Skip to main
TXG

10X Genomics (TXG) Stock Forecast & Price Target

10X Genomics (TXG) Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 18%
Buy 9%
Hold 73%
Sell 0%
Strong Sell 0%

Bulls say

10x Genomics is a life science technology company with a strong outlook due to its innovative product offerings and expanding base of applications. It has experienced double-digit growth in spatial consumables revenue and has a competitive advantage in the market. While there are risks from competition in the single cell market, the company is well-positioned for growth and has a positive outlook for the future.

Bears say

10x Genomics is facing pressure in both its product sales and instrument placements, with a decline in expected 2026 revenue guidance and persistent capex hesitancy leading to flat Chromium consumables sales for the year. Additionally, increased competition and changes in commercial leadership pose risks for the company, potentially limiting its growth and profitability in the future.

10X Genomics (TXG) has been analyzed by 11 analysts, with a consensus rating of Hold. 18% of analysts recommend a Strong Buy, 9% recommend Buy, 73% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 10X Genomics (TXG) Forecast

Analysts have given 10X Genomics (TXG) a Hold based on their latest research and market trends.

According to 11 analysts, 10X Genomics (TXG) has a Hold consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

10X Genomics (TXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.